Problems grow for neuromodulation firm Helius Medical Technologies
Investor Alert: Kaplan Fox Investigates Helius Medical Technologies, Inc. (press release):
“NEW YORK, Feb. 7, 2019 /PRNewswire/ — Kaplan Fox & Kilsheimer LLP has been investigating claims on behalf of investors of Helius Medical Technologiues, Inc. (“Helius” or the “Company”) (Nasdaq: HSDT).
On January 22, 2019, after the market opened, White Diamond Research published an article on Seeking Alpha titled “Helius Medical: A Failed Clinic Trial, Redacted Data, And Questionable Leadership, Points To An Ineffective Device.” The article states that Helius “is a pre-revenue, $200M+ market cap company claiming its only product, the Portable Neuromodulation Stimulator (PoNS) device, can treat a type of brain injury by functional electrical stimulation of the tongue.”
The article by White Diamond Research:
Helius Medical: A Failed Clinical Trial, Redacted Data, And Questionable Leadership, Points To An Ineffective Device (Seeking Alpha):
Article summary:
“Helius Medical is a reverse-merger, single-product, pre-revenue medical device company with a unique device that delivers stimulation to the tongue to treat a type of brain injury.
Evidence suggests the device is likely a placebo, and positive patient results were from the intense physical therapy treatment, not the device.
The founders, which include Montel Williams and the former CEO who is now a fugitive, have a history of questionable marketing practices.
The phase III trial missed its pri...
Source: SharpBrains - Category: Neuroscience Authors: SharpBrains Tags: Cognitive Neuroscience Health & Wellness Technology FDA Helius Medical Helius Medical Technologies PoNS Portable Neuromodulation Stimulator Source Type: blogs
More News: Brain | Clinical Trials | Food and Drug Administration (FDA) | Marketing | Medical Devices | Mergers and Aquisitions | Neurology | Neuroscience | Physical Therapy